Actively Recruiting
Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
Led by University Hospital, Montpellier · Updated on 2025-02-24
24
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Montpellier
Lead Sponsor
C
Centre National de la Recherche Scientifique, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV. One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase). Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.
CONDITIONS
Official Title
Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 years or older
- HIV-positive
- On ART (antiretroviral therapy)
- HIV-1 RNA undetectable for more than 12 months
- Nadir CD4 count < 200/µL
You will not qualify if you...
- Lack of antiretroviral treatment
- Immunosuppressive treatments
- History of cancer less than 5 years old
- Pregnant or breast-feeding women
- Persons protected by law (under guardianship or curators), persons under court protection
- Participating in another research project with an ongoing exclusion period
- Refusal to participate in research
- Subject not affiliated to a social security scheme, or not benefiting from such a scheme.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de MONTPELLIER
Montpellier, France, 34090
Actively Recruiting
Research Team
A
Alain MAKINSON, Pr
CONTACT
B
Bruno BEAUMELLE
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here